A Phase 1 interventional study of MT-6345 and MT-6345 Placebo in Healthy, sponsored by Tanabe Pharma America, Inc.. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects.
Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional screening criteria check may apply for qualification:
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-6345 · Drug: MT-6345 Placebo
Drug: MT-6345 · Drug: MT-6345 Placebo
MT-6345
MT-6345 Placebo
Number of Participants With Mild, Moderate and Severe Adverse Events
The criteria of Mild, Moderate and Severe are as follows: Mild: The event is transient and easily tolerated by the subject. Moderate: The event causes discomfort and interferes with the subject's general condition. Severe: The event causes considerable interference with the subject's general condition and may be incapacitating.
Time frame: Up to 6 weeks
Maximum Plasma Concentration (Cmax) of MT-6345
Cmax was measured for MT-6345 for the PK analysis set (PKPOP) subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Time to Maximum Plasma Concentration (Tmax) of MT-6345
Tmax was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Plasma Terminal Elimination Half Life (t½) of MT-6345
t1/2 was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-6345
AUC(0-24h) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345
AUC(0-last) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345
AUC(0-∞) was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hour. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Terminal Elimination Rate Constant (Kel) of MT-6345
Kel was estimated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Mean Residence Time (MRT) of MT-6345
MRT was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Apparent Oral Clearance (CL/F) of MT-6345
CL/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-t) of MT-6345.
Time frame: up to 2 weeks after dosing
Apparent Volume of Distribution at Steady State (Vss/F) of MT-6345
Vss/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.
Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Linearity Factor (LF) of MT-6345
Time frame: up to 2 weeks after dosing
Accumulation Ratio (RA) of MT-6345
Time frame: up to 2 weeks after dosing
Urinary Excreted Amount of Test Compound (Ae) of MT-6345
Ae was measured for MT-6345 for the PKPOP subjects in Part 3.
Time frame: Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)
Urinary Excreted Amount of Test Compound Expressed as a Percentage of the Dose Administered (Ae%) of MT-6345
Ae% was measured for MT-6345 for the PKPOP subjects in Part 3.
Time frame: Day 1 (pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 16 hours) and Day 2 to Day 10 (pre-dose on each day)
Renal Clearance (CLR) of MT-6345
CLR was measured for MT-6345 for the PKPOP subjects in Part 3. For Day 10, CLR was not calculated because AUC(0-24h) on the last day of dosing was not calculated.
Time frame: Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)
| Milestone | Part 1 and Part 2 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1 and Part 2: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3: Placebo | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 6 | 6 | 6 | 6 | 4 | 5 | 0 | 0 |
| Completed | 10 | 6 | 6 | 5 | 6 | 4 | 5 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 and Part 2 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1 and Part 2: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3: Placebo | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 and Part 2 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1 and Part 2: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3: Placebo | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 |
| Withdrew: Withdrawn by study termination | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 |
The criteria of Mild, Moderate and Severe are as follows: Mild: The event is transient and easily tolerated by the subject. Moderate: The event causes discomfort and interferes with the subject's general condition. Severe: The event causes considerable interference with the subject's general condition and may be incapacitating.
| participants | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: Placebo | Part 2: MT-6345 20 mg | Part 3: Placebo | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | 4 | 0 | 2 | 1 | 2 | 1 | 2 | 0 | 2 | 0 | 2 |
| Moderate | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cmax was measured for MT-6345 for the PK analysis set (PKPOP) subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| ng/mL | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MT-6345 | 8.219 ± 1.414 | 37.37 ± 9.471 | 153.3 ± 38.85 | 386.2 ± 65.23 | 780.9 ± 118.5 | 1522 ± 301.7 | 141.0 ± 42.39 | 523.8 ± 200.7 |
Tmax was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| hour | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of MT-6345 | 0.75 (0.50 to 1.00) | 1.01 (1.00 to 1.52) | 1.00 (0.50 to 2.00) | 1.50 (0.50 to 2.01) | 1.50 (0.50 to 1.50) | 1.50 (1.00 to 1.50) | 2.00 (0.50 to 5.00) | 1.25 (0.50 to 2.00) |
t1/2 was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| hour | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Plasma Terminal Elimination Half Life (t½) of MT-6345 | 34.89 ± 12.54 | 31.83 ± 7.16 | 34.99 ± 8.69 | 44.38 ± 10.76 | 46.03 ± 22.76 | 47.43 ± 31.58 | 39.46 ± 8.96 | 31.09 ± 8.69 |
AUC(0-24h) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| ng.h/mL | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-6345 | 59.6 ± 12.6 | 342 ± 89.6 | 1350 ± 293 | 4050 ± 888 | 7570 ± 634 | 15100 ± 2830 | 1400 ± 288 | 4200 ± 938 |
AUC(0-last) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| ng.h/mL | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345 | 115 ± 28.6 | 776 ± 284 | 3060 ± 1080 | 11100 ± 2590 | 21500 ± 8740 | 41200 ± 20100 | 3590 ± 1200 | 4200 ± 938 |
AUC(0-∞) was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| ng.h/mL | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345 | 126 ± 31 | 786 ± 285 | 3190 ± 1200 | 11200 ± 2640 | 21800 ± 9300 | 42200 ± 21200 | 3650 ± 1200 | 9570 ± 3530 |
Kel was estimated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| /h | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Terminal Elimination Rate Constant (Kel) of MT-6345 | 0.0222 ± 0.0081 | 0.0226 ± 0.0044 | 0.0208 ± 0.005 | 0.0166 ± 0.005 | 0.0176 ± 0.0072 | 0.0198 ± 0.0104 | 0.0182 ± 0.0038 | 0.0244 ± 0.0096 |
MRT was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.
| hour | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Mean Residence Time (MRT) of MT-6345 | 42.1 ± 16.6 | 40.8 ± 10 | 43.9 ± 11.9 | 57.3 ± 14.5 | 58.3 ± 28.6 | 58.8 ± 40.6 | 50.3 ± 9.52 | 42.5 ± 11.9 |
CL/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.
| litre per hour | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of MT-6345 | 8.36 ± 1.93 | 6.89 ± 1.81 | 7.14 ± 2.93 | 5.79 ± 2.15 | 6.16 ± 2.15 | 7.30 ± 4.17 | 5.88 ± 1.60 | 6.92 ± 2.20 |
No measurements were reported for this outcome.
Vss/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.
| litre(s) | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: MT-6345 20 mg | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution at Steady State (Vss/F) of MT-6345 | 335 ± 86.7 | 271 ± 60.3 | 286 ± 39.8 | 318 ± 82.4 | 314 ± 32.2 | 319 ± 85.5 | 284 ± 32.6 | 280 ± 82.4 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Ae was measured for MT-6345 for the PKPOP subjects in Part 3.
| milligram(s) | Part 3: MT-6345 60 mg |
|---|---|
| Day 1 | 0.160 ± 0.0440 |
| Day 10 | 0.255 ± 0.102 |
Ae% was measured for MT-6345 for the PKPOP subjects in Part 3.
| percentage of dose | Part 3: MT-6345 60 mg |
|---|---|
| Day 1 | 0.3 ± 0.1 |
| Day 10 | 0.4 ± 0.2 |
CLR was measured for MT-6345 for the PKPOP subjects in Part 3. For Day 10, CLR was not calculated because AUC(0-24h) on the last day of dosing was not calculated.
| L/h | Part 3: MT-6345 60 mg |
|---|---|
| Renal Clearance (CLR) of MT-6345 | 0.0390 ± 0.0110 |
Collected over From the time written informed consent was obtained from a subject until the end of the Follow-up Period or the withdrawal from the study were recorded, up to 6 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Placebo | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Part 1: MT-6345 1 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1: MT-6345 5 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1: MT-6345 20 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: MT-6345 60 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1: MT-6345 120 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part 1: MT-6345 240 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part 2: Placebo | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part 2: MT-6345 20 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part 3: Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Part 3: MT-6345 60 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 2: Placebo | Part 2: MT-6345 20 mg | Part 3: Placebo | Part 3: MT-6345 60 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/11 | 0/6 | 0/6 | 1/6 | 1/6 | 0/4 | 1/5 | 0/1 | 0/5 | 0/2 | 2/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 1/4 | 0/5 | 0/1 | 0/5 | 0/2 | 0/6 |
| Skin abrasionInjury, poisoning and procedural complications | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/1 | 1/5 | 0/2 | 0/6 |
| NauseaGastrointestinal disorders | 0/11 | 0/6 | 0/6 | 0/6 | 1/6 | 0/4 | 1/5 | 0/1 | 0/5 | 0/2 | 1/6 |
| HaematuriaRenal and urinary disorders | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/4 | 1/5 | 0/1 | 0/5 | 0/2 | 0/6 |
| ErythemaSkin and subcutaneous tissue disorders | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/1 | 1/5 | 0/2 | 0/6 |
| PetechiaeSkin and subcutaneous tissue disorders | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/1 | 1/5 | 0/2 | 0/6 |
| Medical device site reactionGeneral disorders | 1/11 | 0/6 | 1/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/1 | 0/5 | 0/2 | 0/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/11 | 0/6 | 1/6 | 0/6 | 0/6 | 0/4 | 0/5 | 0/1 | 0/5 | 0/2 | 0/6 |
| TachycardiaCardiac disorders | 0/11 | 0/6 | 0/6 | 0/6 | 1/6 | 0/4 | 0/5 | 0/1 | 0/5 | 0/2 | 0/6 |
The analysis population is the subjects of Part 1 and Part 3 since the subjects of part 2 were selected from part 1.
| Age, Customized(Participants) | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3 Placebo | Part 3: MT-6345 60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 18-64 years | 11 | 6 | 6 | 6 | 6 | 4 | 5 | 2 | 6 | 52 |
| Sex: Female, Male(Participants) | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3 Placebo | Part 3: MT-6345 60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 11 | 6 | 6 | 6 | 6 | 4 | 5 | 2 | 6 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3 Placebo | Part 3: MT-6345 60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 6 | 6 | 6 | 6 | 4 | 5 | 2 | 6 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 Placebo | Part 1: MT-6345 1 mg | Part 1: MT-6345 5 mg | Part 1: MT-6345 20 mg | Part 1: MT-6345 60 mg | Part 1: MT-6345 120 mg | Part 1: MT-6345 240 mg | Part 3 Placebo | Part 3: MT-6345 60 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 11 | 6 | 6 | 6 | 6 | 4 | 5 | 2 | 6 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Jul 2019, 5 months.
Results were first posted in Sep 2021, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.